Sophia Abene

A comparative study presented MAD-ID, The Antimicrobial Stewardship Meeting examining the effectiveness of ceftaroline and vancomycin in addressing this challenge.

A study presented at The Annual Conference on Vaccinology Research (ACVR) offers insights into the efficacy of seasonal influenza vaccines.

This week, new WHO data illustrates challenges during the acute phase of the COVID-19 pandemic, MAD-ID and ACVR conference coverage, and more from Contagion.

This study, presented at MAD-ID, The Antimicrobial Stewardship Meeting, evaluates patients with mild COVID-19 symptoms compared to those with severe cases.

Trial analyses presented at MAD-ID, The Antimicrobial Stewardship Meeting, highlight the battle against recurrent health care-associated infections (HAI).

The PERSEUS study aimed to assess the effectiveness and safety of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin presented at the 34th ESCMID Global conference.

Insights from the Annual Conference on Vaccinology Research (ACVR) in mitigating severe outcomes in older adults and individuals with underlying medical conditions.

Insights from the Annual Conference on Vaccinology Research (ACVR) on vaccine registries and assessing the safety of maternal and fetal health.

Investigating the long-term efficacy beyond short-term benefits.

Despite overall reductions, the elderly remain vulnerable to severe COVID-19 outcomes.

The Department of Agriculture has initiated proactive measures, collaborating with federal agencies, to ensure the safety of the nation's meat supply.

This week, April FDA roundup, ESCMID conference coverage, enhancing C difficile treatment, and more from Contagion.

Despite no reported cases of illness associated with the affected products, all retailers who received these items have been duly informed, and the recall is being conducted in coordination with the FDA.

Detection of E coli bacteria and inorganic arsenic in these products raises significant health concerns.

This study monitored viral load in asymptomatic blood donors, unveiling insights into the progression of HEV infections, vital for public health strategies.

Study reveals concerning trends from the mosquito-borne disease impacting Canada and the US.

The Food and Drug Administration (FDA) in collaboration with the Centers for Disease Control and Prevention (CDC) and state and local health partners, are investigating a multistate outbreak of E coli O157:H7 infections linked to organic walnuts.

Insights from Dr. Md Zahidul Alam on treatments and prevention strategies for C difficile infection (CDI), supported by the CDC's recent study on CDI management in healthcare settings.

A study presented at ESCMID examines the efficacy and safety of the vaccine in older populations.

FDA-approves mpox vaccine, FDA grants EUA for at-home multiplex papid test, FDA grants PDUFA for GSK 5-in-1 meningococcal vaccine, and more this month from the FDA.

A study presented at ESCMID aims to understand ribotype 955 as a new challenge in C difficile management.

C-SMART trial results presented at ESCMID show a reduction of COVID-19 incidence in cancer patients.

Insights into host-directed therapies (HDT) for tuberculosis (TB) gaining traction among experts aiming to combat the disease's various forms, including drug-resistant strains.

Insights from Pranay Sinna MD on a multicenter prospective cohort study on household contacts.

In a collaboration between the University of Oxford, the Ministry of Health in Rwanda, and the Rwanda Biomedical Centre, groundbreaking data on the R21/Matrix-M malaria vaccine, marks a significant shift in the malaria paradigm.

Photini Sinnis MD, professor at the Johns Hopkins School of Public Health and Deputy Director of the Johns Hopkins Malaria Research Institute, offers her expert insights into this zoonotic disease.

Study from the Journal of Hepatology aims to characterize immune responses associated with rapid natural clearance of HCV reinfection.

FDA recalls, allergy alerts, e coli & salmonella outbreaks, and more.

Already FDA-approved in the US, TG-1000 confirms safety and prepares for global expansion.

Evaluating inpatient mortality for patients without supplemental oxygen at admission across different variants of concern periods with insights from Dr. Andre Kalil.